Breaking News, Promotions & Moves

Petauri Taps Dan Vanderpoel for Dual Leadership Role

As EVP, Strategic Payer Marketing, and Head, Client Solutions, Vanderpoel will report to CEO Dan Renick.

Petauri, a purpose-built pharmaceutical services platform, has appointed Dan Vanderpoel as Executive Vice President, Strategic Payer Marketing, and Head, Client Solutions.
 
In this newly created dual position, Vanderpoel’s focus will be driving forward-thinking customer solutions and cultivating strategic partnerships to capitalize on synergies across the Petauri platform with current and prospective clients, leveraging his relationships in the pharmaceutical and market access space. Additionally, Vanderpoel will be dedicated to the expansion of Petauri’s existing market access offerings across payer strategies and marketing solutions.

Experience

With over 20 years of market access experience, Vanderpoel has honed his expertise through diverse leadership roles in payer organizations and pharmaceutical service providers. He will report to Petauri CEO, Dan Renick. Their collaboration spans multiple successful past ventures, including roles at Humana, Inc., The Hobart Group, and, most recently, Precision Value & Health.
 
“The market access landscape continues to evolve, presenting opportunities and challenges for the biopharmaceutical industry as companies launch new products and technologies,” said Vanderpoel. “I am thrilled to join the Petauri platform and leverage our expanding suite of services to drive client success in this ever-changing environment.”
 
“Dan brings a wealth of experience and significant industry recognition to Petauri, particularly because of his extensive strategic contributions in market access and payer marketing,” said Renick. “In our prior work together, Dan demonstrated an exceptional talent for identifying and addressing market access obstacles, crucial for ensuring the best patient access to healthcare innovations and medical advances. We are thrilled that he is joining Petauri as we continue our rapid and remarkable expansion.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters